Navigation Links
Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
Date:3/31/2009

Retrospective Analysis Presented at 58th Annual Scientific Session of the American College of Cardiology Suggests Oral Anticoagulants are Underused in Eligible Patients with Non-Valvular Atrial Fibrillation at Risk for Stroke

RIDGEFIELD, Conn., March 31 /PRNewswire/ -- Boehringer Ingelheim today announced that it plans to launch REAL-AF (Registry to Evaluate AnticoaguLation in Atrial Fibrillation), a U.S. based registry to evaluate patterns in the present practice of anticoagulation in 2,500 patients with non-valvular atrial fibrillation (AF).(1) The registry, which will be led by an outside committee of expert advisers,(1) will enroll patients prospectively and analyze data from patients retrospectively.(1)

Atrial fibrillation is the most common abnormal rhythm of the heart and affects more than 2.2 million Americans.(2) Atrial fibrillation can lead to serious health complications such as stroke.(2) In fact, AF is associated with a five-fold increase in the risk of stroke(3) and is associated with up to one out of every six strokes in the U.S.(2) Furthermore, AF-related strokes are often more severe and debilitating than other types.(4,5)

"Stroke can be a serious consequence of atrial fibrillation, particularly among older patients, yet evidence from several analyses suggests that many patients are not receiving anticoagulation for stroke prevention," said Dr. Giora Davidai, executive director and cardiovascular medical leader, Boehringer Ingelheim. "Through this registry, Boehringer Ingelheim hopes to better understand the factors contributing to under-treatment in this patient population."

REAL-AF Registry

Anticoagulant therapy is the most effective approach for stroke prevention in AF, reducing the incidence of stroke by up to 60 percent.(6) However, there is a need for accurate data to define the patterns of current use and management of anticoagulation in pa
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
2. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
3. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
4. Health Plans Increase Use of Health Incentives
5. Area Health Care Providers Announce Plans to Integrate Services
6. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
7. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
8. Precedent Launches Revolutionary Individual Health Insurance Plans in Texas
9. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
10. CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans
11. Delta Dental Plans Association Forms National Scientific Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The need ... In an effort to provide comfort to patients as well as visiting friends and ... solution: free phone charging stations. , The stations - powered by ChargeItSpot , ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ross A. Clevens, MD, FACS has ... Professor of Plastic Surgery. This is Dr. Clevens’ second appointment by the prestigious ... university, developing a strong presence and a valuable mentoring program for medical students. ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... the latest issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, ... of the new issue, Volume 6, Issue 2, as well as past issues ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston ... the annual All-Stars Summit. Google Partners is the platform for search marketing agencies ... full support and tools necessary to run successful search marketing campaigns. Google Partners ...
(Date:7/30/2015)... Wisconsin (PRWEB) , ... July 30, 2015 , ... Quintessa ... Kybella is a nonsurgical treatment designed specifically for the elimination of ... one of the first locations in the state of Wisconsin to offer this innovative ...
Breaking Medicine News(10 mins):Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2
... Experts agree that long-term alcohol abuse is detrimental to ... to a study published in Age and Ageing ... that light-to-moderate alcohol consumption may decrease the risk of ... studies have suggested the prevalence of alcohol-related dementia to ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... announcement Monday that researchers reconfigured immune cells so that they became ... But they say the jury is out on whether the ... is ultimately a cure or what,s called a "functional cure" -- ...
... The National Eye Institute (NEI) and Food and Drug ... functional vision-related endpoints for clinical trials of visual prostheses ... visual acuity, visual fields and contrast sensitivity. These assessments ... test outcomes. Today, functional vision outcomes ...
... Reporter , TUESDAY, March 1 (HealthDay News) -- Half of ... new health care reform law that requires all Americans not ... support it, a new Harris Interactive/HealthDay poll finds. ... seem to sway opinion back toward support for it. ...
... March 1, 2011 The American Sociological Association (ASA) ... dedicated to research on the sociology of mental health ... Health (SMH) journal features original, peer-reviewed studies that ... the social origins of mental health and illness, the ...
... Ohio New research has identified a small subset of ... to a rare incurable form of leukemia. The study, ... Center Arthur G. James Cancer Hospital and Richard J. ... lymphocyte leukemia can occur in a small subset of white ...
Cached Medicine News:Health News:Research suggests alcohol consumption helps stave off dementia 2Health News:Research suggests alcohol consumption helps stave off dementia 3Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 3Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 4Health News:Visual prostheses: Symposium to explore combining functional endpoints 2Health News:Few Support 'Individual Mandate' in Health Care Reform Law, Poll Finds 2Health News:Few Support 'Individual Mandate' in Health Care Reform Law, Poll Finds 3Health News:Few Support 'Individual Mandate' in Health Care Reform Law, Poll Finds 4Health News:ASA launches new journal focused on mental health and illness 2Health News:A small subset of normal white blood cells gives rise to a rare leukemia, study shows 2
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), provided updates regarding the notice it received ... (the "Exchange") indicating that the Company was below certain ... in Sections 134 and 1101 of the NYSE MKT ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... University of Alabama at Birmingham (UAB) Health System became ... to utilize intrafraction motion review (IMR), or "triggered imaging," ... cancer.  IMR, which is a unique capability of the ... VAR ) enables visual verification that a tumor ...
... N.J., Nov. 21, 2011  Omthera Pharmaceuticals, Inc., a ... Jerry Wisler, President and Chief Executive Officer, will ... Piper Jaffray Health Care Conference on Wednesday, November ... York Palace hotel. About Omthera ...
Cached Medicine Technology:Clinicians at the University of Alabama at Birmingham (UAB) Health System First in World to Use "Triggered Imaging" Technology From Varian Medical Systems 2Clinicians at the University of Alabama at Birmingham (UAB) Health System First in World to Use "Triggered Imaging" Technology From Varian Medical Systems 3
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
The Secur-Fit cups incorporate enhancements derived from years of clinical, radiographic, and implant retrieval observations....
The Bofor acetabular revision cup addresses cases of severe acetabular destruction....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: